(2)(2)(2) NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today provided its full-year 2026 guidance while revising its November 4, 2025 full-year 2025 Revenue guidance and reaffirming all other components of full- year 2025 financial guidance. The accompanying presentation can be found at www.pfizer.com/investors. (2)FULL-YEAR 2026 REVENUE GUIDANCE (2)(2)(2)(3) Pfizer anticipates full-year 2026 revenues to be in the range of $59.5 to$62.5 billion, while full-year 2025 revenue guidance is revised to appr ...